Rathbones Group PLC Has $8.09 Million Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Rathbones Group PLC cut its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 0.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,495 shares of the biotechnology company’s stock after selling 245 shares during the period. Rathbones Group PLC’s holdings in Axon Enterprise were worth $8,090,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. 9258 Wealth Management LLC acquired a new stake in Axon Enterprise in the fourth quarter valued at $204,000. Principal Securities Inc. acquired a new stake in Axon Enterprise in the fourth quarter valued at $49,000. Envestnet Portfolio Solutions Inc. increased its holdings in Axon Enterprise by 1.1% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,997 shares of the biotechnology company’s stock valued at $1,033,000 after purchasing an additional 43 shares during the period. Principal Financial Group Inc. increased its holdings in Axon Enterprise by 14.4% in the fourth quarter. Principal Financial Group Inc. now owns 99,556 shares of the biotechnology company’s stock valued at $25,718,000 after purchasing an additional 12,544 shares during the period. Finally, Avantax Advisory Services Inc. increased its holdings in Axon Enterprise by 5.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 5,262 shares of the biotechnology company’s stock valued at $1,359,000 after purchasing an additional 291 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on AXON shares. Jefferies Financial Group started coverage on Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price objective for the company. Bank of America began coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price target on the stock. JMP Securities upped their price target on shares of Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research report on Thursday. Northland Securities upped their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Finally, Barclays upped their price target on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Price Performance

AXON stock opened at $379.61 on Monday. The stock has a market capitalization of $28.69 billion, a PE ratio of 111.00, a price-to-earnings-growth ratio of 10.30 and a beta of 0.94. The company’s 50-day moving average is $338.92 and its 200-day moving average is $314.68. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. Axon Enterprise, Inc. has a 1 year low of $189.12 and a 1 year high of $385.00.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. During the same quarter in the prior year, the firm earned $0.80 EPS. The business’s revenue was up 34.5% on a year-over-year basis. Equities research analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Insider Transactions at Axon Enterprise

In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total transaction of $167,863.50. Following the completion of the sale, the director now owns 7,379 shares in the company, valued at $2,752,588.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Matthew R. Mcbrady sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $364.66, for a total value of $729,320.00. Following the transaction, the director now owns 4,892 shares in the company, valued at approximately $1,783,916.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total value of $167,863.50. Following the sale, the director now directly owns 7,379 shares of the company’s stock, valued at $2,752,588.37. The disclosure for this sale can be found here. Insiders sold a total of 316,981 shares of company stock valued at $115,281,744 over the last ninety days. 6.10% of the stock is currently owned by insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.